Robert Plenge
@rplenge
EVP, Chief Research Officer at BMS; physician-scientist; human genetics; father of 3 girls
ID: 931450722
http://www.plengegen.com 07-11-2012 07:16:34
5,5K Tweet
6,6K Followers
100 Following
We are passionate about our science at BMS. CAR T therapy offers the potential to change the lives of patients with blood cancers and autoimmune diseases. Bristol Myers Squibb bms.com/life-and-scien…
Excited to share the first publication from Oda lab in Nature Immunology !! We describe human SHARPIN deficiency as a novel member of 'inborn errors of cell death'. A great collaboration with Dan Kastner, @Bee191961, and Najoua Lalaoui & the LalaLab. rdcu.be/dEx07
I had the pleasure of speaking with Nature Reviews Drug Discovery about one of the topics I’m most passionate about: the potential of sequential immunotherapy to treat autoimmune diseases. We also discussed genetics and its role in causal human biology. nature.com/articles/d4157…
Another fascinating interview - with Robert Plenge, head of research at Bristol Myers Squibb : Causal biology is the North Star of R&D. (Open access). youtu.be/jG3QEE6wRoM?si… via YouTube
New pre-print from the PGC Consortium #Depression Group: Multi-ancestry GWAS of depression with 685,000 cases identifies 697 independent associations, implicating known & novel drug targets. 🔗 medrxiv.org/content/10.110… 1/n
Tuesday 5/28/24: Biomedical Informatics Entrepreneurs Salon #BIES hosted by Isaac Kohane w/ Harvard OTD 🍕🥤🍪 4:30pm In-person food/drink/network at HMS 🗣️🧠💡5:00–6:00pm (Zoom option) Robert Plenge, Robert Plenge Bristol Myers Squibb Bristol Myers Squibb Register: eventbrite.com/e/bies-robert-…
Looking forward to exploring a successful transition from academia to industry with Robert Plenge this afternoon over food and drink Harvard Medical School for the Biomedical Informatics Entrepreneurs Salon #BIES
New on plengegen.com: How our sequential immunotherapy research strategy Bristol Myers Squibb strives to provide durable remissions and even functional cures for patients with #autoimmune diseases. plengegen.com/blog/seqimm/
Our Head of Research, Robert Plenge, explains the components of our strategic research framework and how our differentiated platforms set us apart. See why he’s excited by the scientific innovation and collaborations underway enabling us to transform patients' lives through science.
Please join us in welcoming Chris Schade, Lynne Parshall, Robert Plenge, and Nancy Simonian, who join Lovisa Afzelius and Michelle Werner on Alltrna’s Board of Directors. Their expertise will help guide us as we advance our first #tRNA medicines to the clinic for #StopCodonDisease
I’m thrilled to share that our work from the VA Research is finally out in Science Magazine ! We dive deep into the genetic architecture of 2,068 traits using data from the VA Million Veteran Program, comprising 635,969 Veteran. science.org/doi/10.1126/sc…
I've noticed that biotech cos built around a computational discovery platform have a different philosophy on company building and how to use software to gain sustainable advantage vs. 'traditional' biotech or pharma. I reflect on this in a new blog post: atelfo.github.io/2024/09/17/a-n…
Jeffrey Flier Really fascinating article on GLP1. Q1: given knowledge in 1997, do you think PFE approached decision in wrong way? Q2: what about calbio - arguably they achieved great exit in relatively short time - seems far less likely for GLP1. Q3: Your POV on decision-making here?
